Use of Venetoclax , AML , Sohag , Egypt
NCT06993883 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43
Last updated 2025-05-29
Summary
retrospective observational study to evaluate the benefit of adding venetoclax to chemotherapy in the first or second line setting in Sohag governorate.
Conditions
- AML (Acute Myelogenous Leukemia)
Interventions
- DRUG
-
observational study for the result of venetoclax use combined with chemotherapy in AML patients in Sohag governorate
Sponsors & Collaborators
-
Sohag University
lead OTHER
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-03-01
- Primary Completion
- 2025-04-30
- Completion
- 2025-04-30
- FDA Drug
- Yes
Countries
- Egypt
Study Locations
More Related Trials
-
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
NCT03826992 ·Status: RECRUITING ·Phase: PHASE1
-
Venetoclax Combined With Homoharringtonine and Cytarabine in Induction for AML
NCT05805098 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Correlation of Venetoclax Plasma Concentrations With Toxicity of Hypometilating Agents and Venetoclax Combination for Acute Myeloid Leukemia Patients in Remission.
NCT07254312 ·Status: RECRUITING
-
Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
NCT04898894 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
NCT03319901 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)
NCT04198415 ·Status: COMPLETED
-
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia
NCT04813263 ·Status: COMPLETED
-
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
NCT05566054 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia
NCT05659992 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia
NCT05918198 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia
NCT06084819 ·Status: RECRUITING ·Phase: PHASE2
-
Venetoclax to Augment Epigenetic Modification and Chemotherapy
NCT05317403 ·Status: RECRUITING ·Phase: PHASE1
-
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML
NCT06429098 ·Status: RECRUITING ·Phase: PHASE2
-
Pharmacokinetics of Venetoclax in Patients With Acute Myeloid Leukemia
NCT04613622 ·Status: RECRUITING
-
Venetoclax Combined With Azacitidine and CAG in Refractory/Relapse Acute Myeloid Leukemia
NCT05807347 ·Status: RECRUITING ·Phase: PHASE2
-
Study of the Relationship Between the Pharmacokinetics (PK) and Pharmacodynamics of Venetoclax in Patients With Acute Myeloblastic Leukemia
NCT07243483 ·Status: RECRUITING ·Phase: NA
-
A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)
NCT04509622 ·Status: COMPLETED ·Phase: PHASE3
-
Venetoclax Registry
NCT03662724 ·Status: RECRUITING
-
Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
NCT03844815 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Venetoclax in Combination With Intensive Induction and Consolidation Chemotherapy in Treatment Naïve AML
NCT03709758 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
NCT03941964 ·Status: COMPLETED ·Phase: PHASE3
-
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
NCT05182385 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
Venetoclax Plus CACAG Regimen for Newly Diagnosed Acute Myeloid Leukemia
NCT06068621 ·Status: COMPLETED ·Phase: PHASE2
-
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
NCT04086264 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
NCT02980731 ·Status: COMPLETED ·Phase: PHASE3